EUCTR2013-001912-31-ES进行中（未招募）不适用
Randomised, double-blind, placebo-controlled, multi-centre trial on the efficacy and safety of budesonide for induction of remission in incomplete microscopic colitis - Budesonide for induction of remission in incomplete microscopic colitis
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 106
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Signed informed consent,
- •2.Man or woman between 18 and 80 years of age,
- •3.Histologically established diagnosis of incomplete microscopic colitis (MCi) defined as the following findings in at least two segments of the colon:
- •- increased lymphoplasmacellular infiltrate in the lamina propria and
- •- thickened subepithelial collagenous band > 5 ?m and < 10 ?m and/or
- •- abnormal intraepithelial lymphocytes > 5 and < 20 per 100 epithelial cells,
- •4.History of chronic non-bloody, watery diarrhoea for at least 4 weeks,
- •5.Clinically active disease (defined as a mean of ? 3 stools/day, thereof a mean of ? 1 watery stool/day during the week prior to randomisation),
- •6.Women of child-bearing potential have to apply during the entire duration of the study a highly effective method of birth control, which is defined as those which result in a low failure rate (i.e., less than 1% per year) when used constantly and correctly such as implants, injectables, combined oral contraceptive method, some IUDs, sexual abstinence or vasectomised partner. The investigator is responsible for determining whether the patient uses adequate birth control for study participation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 26
排除标准
- •1.Other significant abnormalities in colonoscopy that may have been the cause of diarrhoea except for colonic diverticulosis and non-dysplastic polyps < 2 cm,
- •2.Infectious cause of diarrhoea (local routine stool samples, Clostridium difficile included) or history of infectious diarrhoea within the last 3 months prior inclusion or local intestinal infection,
- •3.Clinical suspicion of drug-induced diarrhoea,
- •4.Prior and present MC (i.e., all histological criteria for collagenous colitis or lymphocytic colitis fulfilled),
- •5.History of bowel resection,
- •6.Radiation therapy of the abdominal or pelvic region,
- •7.Positive antibody titres for celiac disease (tGT IgA + serum IgA),
- •8.Untreated active thyroid dysfunction,
- •9.Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder reducing life expectancy,
- •10.Abnormal hepatic function (ALT or ALP > 2.5 x upper limit of normal [ULN]), liver cirrhosis, or portal hypertension,
- •11.Tuberculosis, hypertension, diabetes mellitus, osteoporosis, peptic ulcer disease, glaucoma, cataract, or infection if careful medical monitoring is not ensured,
- •12.History of colorectal cancer,
- •13.History of cancer (other than colorectal) in the last 5 years,
- •14.Therapy with immunomodulators (e.g., azathioprine, 6-mercaptopurine, or methotrexate) within 3 months prior to baseline,
- •15.Treatment with budesonide or other steroids within 4 weeks prior to baseline,
- •16.Treatment with antibiotics within 4 weeks prior to baseline,
- •17.Treatment with anti-diarrhoeal drugs (e.g., loperamide, ispaghula, codeine, and opium), cholestyramine, bulking agents, and spasmolytics within 2 weeks prior to baseline,
- •18.Known intolerance/hypersensitivity/resistance to the trial drug or drugs of similar chemical structure or pharmacological profile,
- •19.Current or intended pregnancy or breast-feeding,
- •20.Doubt about the patients cooperation, e.g. because of addiction to alcohol or drugs,
- •21.Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial.
研究者
相似试验
进行中（未招募）
1 期
Randomised, double-blind, placebo-controlled, multi-centre trial on the efficacy and safety of budesonide for induction of remission in incomplete microscopic colitis - Budesonide for induction of remission in incomplete microscopic colitisEUCTR2013-001912-31-PTDr. Falk Pharma GmbH44
进行中（未招募）
不适用
Randomised, double-blind, placebo-controlled, multinational, multi-centre, Phase IIb / III study of the efficacy and safety of three doses of sublingual immunotherapy (SLIT) administered as tablets once daily to patients suffering from grass pollen rhinoconjunctivitisGrass Pollen Related Allergic RhinoconjunctivitisMedDRA version: 7.0Level: PTClassification code 10010744EUCTR2004-001910-15-ATStallergenes S.A.600
进行中（未招募）
1 期
Randomised, double-blind, placebo-controlled, multi-centre trial on the efficacy and safety of budesonide for induction of remission in incomplete microscopic colitisEUCTR2013-001912-31-DKDr. Falk Pharma GmbH106
进行中（未招募）
1 期
ovel budenosid suppository in addition to basic therapy with oral mesalazine compared to basic therapy alone for treatment of ulcerative colitisacute ulcerative colitisMedDRA version: 20.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000004856EUCTR2019-003334-16-BGDr. Falk Pharma GmbH360
进行中（未招募）
不适用
Randomised, double-blind, placebo-controlled, multinational, multi-centre, Phase IIb / III study of the efficacy and safety of three doses of sublingual immunotherapy (SLIT) administered as tablets once daily to patients suffering from grass pollen rhinoconjunctivitisGrass Pollen Related Allergic RhinoconjunctivitisMedDRA version: 7.0Level: PTClassification code 10010744EUCTR2004-001910-15-DKStallergenes S.A.600